Few universally fatal diseases have benefited from therapy to the extent that irreversible uremia has responded to maintenance hemodialysis and renal transplantation. Before 1960, when Scribner and co-workers devised a regimen for repetitive hemodialysis1 every chronic uremic patient with the exception of monozygotic twin kidney recipients had no hope of living more than a few weeks once residual renal function fell below a creatinine clearance of 2 ml/min. In 1980, a choice of three effective therapies, each capable of prolonging useful life for years, are available to preempt death in renal failure (Figure 1).
KeywordsPeritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Uremic Patient Maintenance Hemodialysis Residual Renal Function
Unable to display preview. Download preview PDF.
- 1.Hegstrom, R. M., Murray, J. S., Pendras, J. P., et al. Hemodialysis in the treatment of chronic uremia. Transactions of the American Society of Artificial Internal Organs, 1961, 7, 136–149.Google Scholar
- 3.Popovich, R. P., Moncrief, J. W., Decherd, J. B., et al. The definition of a novel portable/wearable equilibrium peritoneal dialysis technique. American Society of Artificial Internal Organs, 1976, 5, 64.Google Scholar
- 4.Oreopoulos, D. G. The coming of age of continuous ambulatory peritoneal dialysis (CAPD), Dialysis and Transplantation, 1979, 8, 460–461.Google Scholar